Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.
Lejeune
Ferdy J
FJ
Multidisciplinary Oncology Center, Lausanne University Hospital, Lausanne, Switzerland. Fredy.leyeune@chuv.hospvd.ch
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002199:Capillary Permeability / Q000187:drug effects; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D016228:Endothelial Growth Factors / Q000494:pharmacology; D008222:Lymphokines / Q000494:pharmacology; D051379:Mice; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000970:Antineoplastic Agents; D016228:Endothelial Growth Factors; D008222:Lymphokines; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors